70.66 -0.21 (-0.30%)
After hours: 6:59PM EDT
|Bid||69.95 x 1300|
|Ask||80.00 x 1800|
|Day's range||70.44 - 71.52|
|52-week range||62.52 - 78.38|
|Beta (3Y Monthly)||0.89|
|PE ratio (TTM)||43.16|
|Earnings date||31 Oct 2018|
|Forward dividend & yield||0.76 (1.07%)|
|1y target est||80.15|
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.
Abbott Laboratories (ABT) offers market-leading products and solutions across its Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals operating segments.
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.
Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.
On September 26, Abbott Laboratories (ABT) ended the trading day at $72.84, up ~0.89% from the previous day’s close. Abbott Laboratories reported its 52-week low of $51.55 a year ago on September 27, 2017. Abbott Laboratories has risen ~38% over the last 12 months.
Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price. The stock has maintained growth momentum over the last year.
Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
In the first quarter of fiscal 2019, Medtronic’s (MDT) Minimally Invasive Therapies Group reported revenue of $2.1 billion compared to $2.5 billion in the fiscal first quarter of 2018, reflecting a ~17% YoY (year-over-year) fall.
In 2012, Baxter International (BAX) adopted a $2 billion share buyback program. In November 2016 and February 2018, the company increased the program by $1.5 billion each.
Sales from Baxter International’s (BAX) advanced surgery business, which includes biological products and medical devices that are used in surgical procedures, increased from $178 million in the second quarter of 2017 to $204 million in the second quarter of 2018. The marketing and administrative expenses incurred by Baxter International increased from $630 million in the second quarter of 2017 to $681 million in the second quarter of 2018.
Baxter International’s (BAX) global business units include renal care, medication delivery, pharmaceuticals, nutrition, advanced surgery, acute therapies, and other, which primarily includes sales from Baxter’s pharmaceutical partnering business. Baxter International generated revenue of $2.84 billion in the second quarter compared to $2.6 billion in the comparable period in 2017. Baxter International incurred a cost of sales of $1.6 billion in the second quarter compared to $1.47 billion in the second quarter of 2017.